Alemtuzumab, cladribine, fingolimod, and natalizumab as first-line treatments in patients with highly active relapsing multiple sclerosis (Last Updated: Feb 9, 2022)
Please note that this topic is under review and will not necessarily be selected for a Health Technology Assessment or Optimal Use project. Detailed Information Page about Topics under Consideration...
Health Technology Review
Topics Under Consideration